Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEROES: De-escalation of Medical Therapies in HER2-positive Metastatic Breast Cancer
NCT06450314Phase 2Recruiting
- Sponsor
- Unicancer
- Start
- Jan 2025
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in HER2-positive breast cancer, sponsored by Unicancer. Primary endpoint: Progression-free rate at 1 year. Started Jan 2025; status: recruiting.
02
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT06450314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06450314.